International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Commentary: Sex differences in immune responses that underlie COVID-19 disease outcomes

computer with words expert commentary

Errol Prens, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands
IPC Councilor

PUBLICATION

Sex differences in immune responses that underlie COVID-19 disease outcomes. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, Silva J, Mao T, Oh JE, Tokuyama M, Lu P, Venkataraman A, Park A, Liu F, Meir A, Sun J, Wang EY, Casanovas-Massana A, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ; Yale IMPACT Research Team, Shaw A, Fournier JB, Odio CD, Farhadian S, Dela Cruz C, Grubaugh ND, Schulz WL, Ring AM, Ko AI, Omer SB, Iwasaki A. Nature. 2020 Dec;588(7837):315-320. doi: 10.1038/s41586-020-2700-3. Epub 2020 Aug 26. PMID: 32846427; PMCID: PMC7725931.

COMMENTARY

Because of the growing body of evidence indicating sex differences in the clinical outcomes of coronavirus disease 2019 (COVID-19) infection, the IMPACT Research Team from Yale University investigated sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients. They discovered essential differences in immune responses during the disease course of SARS-CoV-2 infection in male versus female patients. First, they found that the levels of important pro-inflammatory innate immune chemokines and cytokines such as IL-8, IL-18 (at baseline), and CCL5 (longitudinal analysis) were higher in male patients, which correlated with more elevated non-classical monocytes (at baseline) and more severe disease. Second, they observed a more robust T cell response among female patients than male patients at baseline. Collectively, their data suggest that vaccines and therapies to elevate T cell immune response to SARS-CoV-2 might be warranted for male patients. In contrast, female patients might benefit from therapies that dampen innate immune activation early during disease. The immune landscape in COVID-19 patients is considerably different between the sexes. They conclude that these differences may underlie heightened disease susceptibility in men.

The authors recognize an important limitation of their study: healthy healthcare workers who served as controls were not matched to patients based on age, BMI, or underlying risk factors. Despite their corrections for those confounders in their statistical analyses, residual confounding is not ruled out due to underlying risk factors not available for the healthcare workers’ controls. The limited sample size of this study is an explicit limitation.

Categories

Recent Posts

Getting to Know IPC’s Board Member Claudia de la Cruz: What Inspired Me to Specialize in Psoriasis

Introducing Our Latest IPC Councilors: Experts in Psoriasis Treatment and Research

Shining a Spotlight: Catching up with 2018 IPC Fellow, Jia Qi Chen, PhD

Also Read

commentary

Commentary: Efficacy and Safety of Oral Roflumilast for Moderate to Severe Psoriasis—A Randomized Controlled Trial (PSORRO)

In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.